Medigard Ltd. has recently announced an exclusive worldwide license agreement with Kunovus Pty Ltd. under which Medigard will commercialize the patented KT009 injectable product to treat intervertebral disc degeneration (IVDD), debilitating Degenerative Disk Disease (DDD), chronic lower back pain and maybe osteoarthritis (OA). Medigard's role in this development program will be to bring KT009 towards a later pharmaceutical company transaction, potentially combining the KT009 biologic within a custom syringe product as a prefilled syringe product. Medigard has in licensed granted US patents 8,828,941 and 9,480,819, another patent application and extensive know-how on attractive commercial terms and in a deal which does not require the issuing of any shares to the Licensee. The Medigard team is presently obtaining quotations for the conduct of the development program - making clinical grade recombinant KT009, conducting preclinical testing of the clinical grade agent and then running a small scale human trial in Australia in patients suffering intervertebral disc degeneration or degenerative disc disease. Medigard will need to invest into this development program over the next 3 years. The costs of back pain treatment, absenteeism and disablement exceed all other musculoskeletal conditions. The potential market for KT009 is around 30 million patients in the USA alone.